RxDoctor Payments DataLook up a doctor →

Nirmal Sunkara, MD

Interventional Cardiology · Orange, CANPI 1396908141

Payments from drug & device makers

$300,518in general payments, 2019–2025

Across 605 payments — averaging $496.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$174K
  • Novo Nordisk AS$92K
  • AstraZeneca$13K
  • Astrazeneca UK Limited$8K
  • Medtronic$4K
  • GSK$2K
  • plus $6K from 14 others
$1,807in research payments, 2019–2025

Across 1 payment — averaging $1806.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$300,518 in reported general payments places this provider in the 90th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$114,099
Medicare patients
580
Services billed
1,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →